Biotech and drug-innovation themes continue to dominate markets—from AI-driven drug discovery to blockbuster obesity treatments—and a new ETF filing suggests asset managers want a piece of that ...

Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.

Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. Products that are ...

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

Fri, January 16, 2026 at 1:06 PM UTC Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

VanEck Biotech ETF receives a Hold rating due to mixed outlooks among its top holdings and unattractive valuation metrics. BBH's heavy concentration in Amgen, Gilead Sciences, and Vertex ...

Sold 24,270 shares of IBB; estimated trade value of $3.50 million based on quarterly average pricing. Net position value decreased by $3.50 million. Represents a 3.27% shift in 13F reportable assets ...